Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Epidermal growth factor receptor (EGFR) inhibition is a key treatment for epithelial cancers like head and neck squamous cell carcinoma (HNSCC).
• Less than 20% of patients respond to EGFR inhibition due to intrinsic and acquired resistance, limiting its effectiveness.
• Overcoming resistance to EGFR inhibition could significantly improve outcomes across multiple cancer types.

Purpose of the Study:

• To explore mechanisms of intrinsic and acquired resistance to EGFR inhibition in epithelial malignancies.
• To investigate the potential of targeting COX-2 as a strategy to overcome acquired resistance pathways.
• To evaluate the promise of combined EGFR and COX-2 inhibition in HNSCC treatment.

Main Methods:

• Review of mechanisms of intrinsic resistance, including EGFR receptor mutations.
• Analysis of acquired resistance pathways such as EGFR degradation, cMET/HER3, PI3K/Akt, angiogenesis, and epithelial-mesenchymal transition.
• Examination of preclinical data and completed clinical trials on combined EGFR and COX-2 inhibition.

Main Results:

• Intrinsic resistance mechanisms often require alternative therapeutic approaches.
• Acquired resistance pathways are amenable to pharmacological intervention.
• Preclinical data suggest COX-2 inhibitors can modulate multiple acquired resistance pathways.
• Completed trials of combined EGFR and COX-2 inhibition show promise for HNSCC.

Conclusions:

• Targeting COX-2 presents a promising strategy to overcome acquired resistance to EGFR inhibition.
• Combinatorial therapies involving EGFR, COX-2, and other resistance pathways warrant further investigation.
• Combined inhibition strategies with radiation or chemotherapy are recommended for HNSCC treatment.